£192.99

Burkitt Lymphoma: Updates in Etiology, Symptoms, Molecular Genetics and Treatment Options

Oncology

Price data last checked 57 day(s) ago - refreshing...

View at Amazon

Price History & Forecast

Last 34 days • 34 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 34 days • 1 price levels

Days at Price

Price Analysis

Most common price: £193 (34 days, 100.0%)

Price range: £193 - £193

Price levels: 1 different prices over 34 days

Description

Burkitt lymphoma (BL) is a lymphoid neoplasm originating from a mature, follicular center B-cell that is phenotypically positive for CD10, BCL-6, LOM2, and HGAL, with a hallmark genetic translocation involving the MYC gene (at 8q24) and its partner either immunoglobulin heavy chain (14q) or light chain (kappa at 2q and lambda at 22q) and a very aggressive clinical nature. BL can be divided into three clinical subcategories: Endemic, sporadic and HIV/AIDS/immunodeficiency with prevalence in children, adolescents and young adults. Clinical manifestations could slightly be variable upon its clinical subcategories; however, they share certain similar features, e.g., fast growing mass, frequent extranodal presentation, are associated with EBV infection, and sensitive to tumor reduction therapy with a high risk of tumor lysis syndrome and uric acid nephropathy. It is important to differentiate BL from other aggressive types of B-cell lymphomas as with intensive, short-term chemotherapy, (eg: hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine). Additionally, CNS prophylaxis BL showed a much better clinical response. Nearly all types of BL lack or dimly express BCL-2, differentiating it from other mimickers. A diagnostic challenging variant of BL an MYC-negative harboring 11q abnormalities, namely Burkitt-like lymphoma with an 11q aberration has been recently proposed. Novel next generation sequencing and gene expression profiling has brought about new insights into BL. TCF3(E2A), a transcription factor involving the regulation of lymphoid cell survival and proliferation, its negative regulator known as ID3, and the downstream gene CCND3 were also frequently mutated in cases of BL. The characterization of molecular biology and the genetic profile of BL leads to the future of personalized medicine and targeted therapy. This book focuses on the epidemiology, etiology, clinical presentations/staging, differential diagnoses, MYC-driven pathogenesis and therapeutic options concerning BL. These updates in BL and associated EBV- or MYC-positive diseases will benefit trainees, physicians and basic scientists who engage in the diagnosis, treatment, and novel drug development for this disease.

Product Specifications

Format: hardcover
ASIN: 153614164X
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Diseases & Disorders > Oncology
Domain: Amazon UK
Release Date: 18 October 2018
Listed Since: 30 June 2018

Barcode

No barcode data available

Burkitt Lymphoma: Updates in Etiology, Symptoms, Molecular Genetics and Treatment Options

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

The Peripheral T-Cell Lymphomas

Follicular Lymphoma and Mantle Cell Lymphoma: Pathobiology, Diagnosis and Treatment (Molecular and Translational Medicine)

Hematologic Malignancies: An Overview - Hematology Research

Atlas of Hematologic Neoplasms

Springer - Burkitt's Lymphoma (Current Cancer Research)

Burkitt’s Lymphoma (Current Cancer Research)

Resistance to Targeted Therapies in Lymphomas: 21 (Resistance to Targeted Anti-Cancer Therapeutics, 21)

Springer - Advances in Biology and Therapy of Multiple Myeloma 2

T-Cell Lymphomas (Contemporary Hematology)

Myeloproliferative Disorders: Symptoms, Risk Factors and Treatment Options (Recent Advances in Hematology Research)

Chronic Lymphoid Leukemias: 26 (Basic and Clinical Oncology)

Aggressive Lymphomas (Hematologic Malignancies)

Diagnostic and Therapeutic Advances in Hematologic Malignancies: 99 (Cancer Treatment and Research, 99)

Springer Malignant Lymphomas and Hodgkin's Disease Volume 66

Ablashi: ∗epstein–bar Virus∗ & Human Disease 1988: 20 (Experimental Biology and Medicine, 20)

Chronic Lymphocytic Leukemia: Pathobiology, B Cell Receptors, Novel Mutations, Clonal Evolution (Molecular and Translational Medicine)

Malignant lymphomas, including Hodgkin’s disease: Diagnosis, management, and special problems: 66 (Cancer Treatment and Research, 66)

Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances: Proceedings of the Second International Conference on Malignant ... – 16, 1984: 32 (Developments in Oncology, 32)

Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances: Proceedings of the Second International Conference on Malignant ... – 16, 1984: 32 (Developments in Oncology, 32)

Diagnostic Pathology: Lymph Nodes and Extranodal Lymphomas

Diagnosis and Therapy of Malignant Lymphoma: 46 (Recent Results in Cancer Research, 46)

Normal and Malignant Hematopoieses: New Advances - Proceedings of the Sixth Pezcoller Symposium Held in Rovereto, Italy, June 29-July 1, 1994: v. 6

The International Consensus Classification of Myeloid and Lymphoid Neoplasms

Advances in Cancer Research: 84: Volume 84